Global Spinal Muscular Atrophy (SMA) Treatment Industry Insights: Market Size, Growth Analysis and Forecast
Report ID : 1366494 | Published : June 2025 | Study Period : 2023-2033 | Format : PDF + Excel
The market size of the Spinal Muscular Atrophy (SMA) Treatment Industry is categorized based on Drug Type (Gene Therapy, Nusinersen, Onasemnogene abeparvovec, Small Molecule Drugs, Supportive Care Medications) and Administration Route (Intrathecal, Oral, Intravenous, Subcutaneous) and Patient Type (Pediatric Patients, Adult Patients) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).
The Spinal Muscular Atrophy (SMA) Treatment Industry was worth $3.5 billion in 2023 and is forecasted to reach $12.4 billion by 2033, growing at a CAGR of 13.5% over the period 2024-2033. This report covers various segments and analyzes the key trends and factors influencing the market significantly.
Spinal Muscular Atrophy (SMA) is an uncommon genetic disorder that is caused by the progressive loss of motor neurons in the spinal cord, resulting in weakness and eventual wasting of muscles. This condition occurs first and foremost in infants and young children, greatly limiting their daily activities and motor skills. With the knowledge of SMA on the rise and new treatment options on the horizon due to the evolution of medical research, the SMA treatment market is expanding quite rapidly. This developing market is largely fueled by the apparent need to find effective therapies, as well as research and clinical efforts to create and develop new solutions that address the needs of the patients.
The last few years have seen massive changes in SMA treatment with the advent of new gene therapies and other modalities. These not only provide a ray of hope to the patients, but also offer distinctly interesting prospects to the various stakeholders in the healthcare ecosystem including pharma companies, healthcare providers, and investors among others. As aims to double the size of the market, a sharp understanding of the competitive landscape, regulatory landscape and patient population will be important for companies seeking to operate in that ever-changing sector. Verified Industry Insights is focused on producing in-depth industry market reports aimed at providing players in the industry with SMA treatment which is growing rapidly due to the changes being made.
| ATTRIBUTES | DETAILS |
| STUDY PERIOD | 2023-2033 |
| BASE YEAR | 2023 |
| FORECAST PERIOD | 2024-2033 |
| HISTORICAL PERIOD | 2023-2024 |
| UNIT | VALUE (USD BILLION) |
| KEY COMPANIES PROFILED | Novartis, Biogen, Roche, AveXis, Sarepta Therapeutics, PTC Therapeutics, Eisai Co. Ltd., Akcea Therapeutics, Genentech, Bristol-Myers Squibb, UCB |
| SEGMENTS COVERED |
By Drug Type - Gene Therapy, Nusinersen, Onasemnogene abeparvovec, Small Molecule Drugs, Supportive Care Medications
By Administration Route - Intrathecal, Oral, Intravenous, Subcutaneous
By Patient Type - Pediatric Patients, Adult Patients
By Geography - North America, Europe, APAC, Middle East Asia & Rest of World. |
Spinal Muscular Atrophy (SMA) Treatment Industry Dynamics
The Spinal Muscular Atrophy (SMA) Treatment Industry is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.
Market Drivers
- Technological Advancements
- Increasing Consumer Demand
- Regulatory Support
- Globalization
Market Restraints
- High Operational Costs
- Regulatory Challenges
- Market Saturation
Market Opportunities
- Emerging Markets
- Product Innovation
- Strategic Partnerships
Market Challenges
- Technological Disruptions
- Supply Chain Issues
- Changing Consumer Preferences
Spinal Muscular Atrophy (SMA) Treatment Industry Segmentations
Market Breakup by Drug Type
- Overview
- Gene Therapy
- Nusinersen
- Onasemnogene abeparvovec
- Small Molecule Drugs
- Supportive Care Medications
Market Breakup by Administration Route
- Overview
- Intrathecal
- Oral
- Intravenous
- Subcutaneous
Market Breakup by Patient Type
- Overview
- Pediatric Patients
- Adult Patients
Market Breakup by Region
North America
- United States of America
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Players in the Spinal Muscular Atrophy (SMA) Treatment Industry
This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.
- Novartis
- Biogen
- Roche
- AveXis
- Sarepta Therapeutics
- PTC Therapeutics
- Eisai Co. Ltd.
- Akcea Therapeutics
- Genentech
- Bristol-Myers Squibb
- UCB
Customization Options
Verified Industry Insights offers one of the following report customization options to our respectable clients :
Company Profiling
● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)
Competitive Benchmarking
● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research
Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439
© 2024 Verified Industry Insights. All Rights Reserved